

Appendix A

10/507500

Claim Amendments

DT04 Rec'd PCT/PTO 13 SEP 2004

1. (Currently amended) ~~Use of~~ A method of treating an airway disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a proton pump inhibitors in the treatment of airway disorders inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, hydrate of a salt or solvate of a salt thereof.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Original) Ready-to-use medicament comprising a proton pump inhibitor as active compound and a reference to the fact that it can be employed for the treatment of airway disorders.

7. (Currently amended) The method of claim 1 ~~Proton pump~~
~~inhibitor as mentioned in any of Claims 1 to 6,~~
~~characterized in that it is a compound~~ wherein the
proton pump inhibitor is selected from the group
consisting of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-
pyridinyl)methylsulphonyl]-1H-benzimidazole (INN:
omeprazole), 5-methoxy-2-[(S)-[(4-methoxy-3,5-
dimethyl-2-pyridinyl)methyl]sulphonyl]-1H-
benzimidazole (INN: esomeprazole), 2-[3-methyl-4-
(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulphonyl]-
1H-benzimidazole (INN: lansoprazole), [[and]] 2-[[4-
(3-methoxypropoxy)-2-methylpyridin-2-yl]-
methylsulphonyl]-1H-benzimidazole (INN: rabeprazole),
~~and in particular~~ 5-difluoromethoxy-2-[(3,4-dimethoxy-
2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN:
pantoprazole), [[and]] (-)-5-difluoromethoxy-2-[(3,4-
dimethoxy-2-pyridinyl)methylsulphonyl]-1H-
benzimidazole (INN: (-)-pantoprazole) and a
pharmaceutically acceptable salt, hydrate, solvate,
hydrate of a salt or solvate of a salt thereof ~~their~~
~~pharmacologically acceptable salts.~~

8. (Currently amended) The method of claim 1, wherein the
proton pump inhibitor ~~Proton pump inhibitor~~ as
~~mentioned in any of claims 1 to 6,~~ characterized in
~~that it is~~ pantoprazole or a ~~pharmacologically~~
~~acceptable salt~~ pharmaceutically acceptable salt,
hydrate, solvate, hydrate of a salt or solvate of a
salt thereof.
9. (Currently amended) The method of claim 1, wherein the
airway ~~Airway~~ disorder ~~as mentioned in any of Claims 1~~
~~to 6,~~ characterized in that it is selected from the
group consisting of bronchitis, COPD, asthma,
pneumonitis ~~[[or]]~~ and pulmonary fibrosis.
10. (New) The method of claim 1, wherein the proton pump
inhibitor is selected from the group consisting of
pantoprazole sodium sesquihydrate, (-)-pantoprazole
sodium sesquihydrate, pantoprazole magnesium
dihydrate, omeprazole-magnesium, omeprazole-magnesium
tetrahydrate, esomeprazole-magnesium and esomeprazole-
magnesium tetrahydrate.